Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 28, Issue -, Pages 57-68Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2016.03.003
Keywords
-
Categories
Funding
- Arthritis Research UK [19205]
- British Heart Foundation [PG/15/13/31296]
- British Heart Foundation [PG/15/13/31296] Funding Source: researchfish
- Versus Arthritis [19205] Funding Source: researchfish
Ask authors/readers for more resources
Inorganic pyrophosphate has long been known as a by-product of many intracellular biosynthetic reactions, and was first identified as a key endogenous inhibitor of biomineralisation in the 1960s. The major source of pyrophosphate appears to be extracellular ATP, which is released from cells in a controlled manner. Once released, ATP can be rapidly hydrolysed by ecto-nucleotide pyrophosphatase/phosphodiesterases to produce pyrophosphate. The main action of pyrophosphate is to directly inhibit hydroxyapatite formation thereby acting as a physiological 'water-softener'. Evidence suggests pyrophosphate may also act as a signalling molecule to influence gene expression and regulate its own production and breakdown. This review will summarise our current understanding of pyrophosphate metabolism and how it regulates bone mineralisation and prevents harmful soft tissue calcification.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available